Dutch
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Adjustment of DOses of NIcotine in Smoking Cessation (ADONIS)

Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
De link wordt op het klembord opgeslagen
ToestandVoltooid
Sponsors
Assistance Publique - Hôpitaux de Paris
Medewerkers
French Health Products Safety Agency

Sleutelwoorden

Abstract

Nicotine replacement therapies (NRT) have proven efficacy to help smokers quit. However, their effectiveness is low. This study aims to answer the question: Does the dose adjustment of NRT according the saliva concentration of nicotine's main metabolite: cotinine improve their efficacy compared with the lack of dose adjustment (usual care) in smoking patients with smoking related disease condition.

Omschrijving

Smokers currently smoking at least 10 cigarettes per day with smoking related diseases are included. They are randomized either to receive standard nicotine replacement therapy (24 h nicotine patch 21, 14, 7 mg/day for one month each, respectively), control arm, or nicotine dose adjustment according their saliva cotinine: dose adaptation arm. In the control arm, at the discretion of the investigators, buccal forms of nicotine replacement therapies are allowed. In both arms, saliva cotinine determinations are performed every 2 weeks for 2 months. In the control arm saliva cotinine results are not communicated to the investigators. In the dose adaptation arm investigators receive saliva cotinine results and should adapt the nicotine doses (mg of nicotine/day) according to baseline (when smoking) saliva cotinine to obtain 100 % substitution. Smokers are assessed at weekly visits after the predetermined quit day for 3 months. Follow up at 6 months. Main outcome measure: sustained abstinence (self reported no smoking and expired air carbon monoxide concentration equal or less than 8 ppm during the last (3rd) month of the treatment phase.

Datums

Laatst geverifieerd: 02/28/2007
Eerste ingediend: 10/05/2005
Geschatte inschrijving ingediend: 10/05/2005
Eerst geplaatst: 10/09/2005
Laatste update ingediend: 03/27/2008
Laatste update geplaatst: 03/31/2008
Werkelijke startdatum van het onderzoek: 09/30/2005
Geschatte primaire voltooiingsdatum: 10/31/2007
Geschatte voltooiingsdatum van het onderzoek: 10/31/2007

Conditie of ziekte

Smoking Cessation

Interventie / behandeling

Procedure: 1

Drug: 2

Fase

Fase 4

Armgroepen

ArmInterventie / behandeling
Experimental: 1
adaptation of the nicotine patch with salivary cotinine
Procedure: 1
Dose adjustment of nicotine replacement therapies
Other: 2
normal following with a nicotine patch
Drug: 2
normal following with a nicotine patch

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie 18 Years Naar 18 Years
Geslachten die in aanmerking komen voor studieAll
Accepteert gezonde vrijwilligersJa
Criteria

Inclusion Criteria:

- Age ≥18 years Smoking ≥ 10 cigarettes per day Patients with disease conditions known to be related to smoking: e.g.coronary heart diseases, COPD, lower extremity arterial disease, etc

Exclusion Criteria:

- Smokers whose follow-up during the duration of the study, in a predictable way, cannot be assured.

- smokers having been treated by bupropion ( Zyban) during two months preceding the inclusion

- persons under TSN, neuroleptic, substitute treatments in OPINOIDES, under anticoagulants-non-equilibrating,

- encircled woman

- breast-feeding woman

- Contraindication usual of the TSN

Resultaat

Primaire uitkomstmaten

1. sustained smoking abstinence [during the study]

Secundaire uitkomstmaten

1. point prevalence abstinence,craving for tobacco,symptoms of nicotine withdrawal,weight,saliva cotinine concentration,genetic polymorphisms as predictors of therapeutic response and in interaction with nicotine replacement therapies [during the study]

Word lid van onze
facebookpagina

De meest complete database met geneeskrachtige kruiden, ondersteund door de wetenschap

  • Werkt in 55 talen
  • Kruidengeneesmiddelen gesteund door de wetenschap
  • Kruidenherkenning door beeld
  • Interactieve GPS-kaart - tag kruiden op locatie (binnenkort beschikbaar)
  • Lees wetenschappelijke publicaties met betrekking tot uw zoekopdracht
  • Zoek medicinale kruiden op hun effecten
  • Organiseer uw interesses en blijf op de hoogte van nieuwsonderzoek, klinische onderzoeken en patenten

Typ een symptoom of een ziekte en lees over kruiden die kunnen helpen, typ een kruid en zie ziekten en symptomen waartegen het wordt gebruikt.
* Alle informatie is gebaseerd op gepubliceerd wetenschappelijk onderzoek

Google Play badgeApp Store badge